Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 238,226,772 papers from all fields of science
Search
Sign In
Create Free Account
dabrafenib
Known as:
Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-
An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
11 relations
Broader (4)
Antineoplastic Agents
Imidazoles
Oximes
Protein Kinase Inhibitors
Breast Cancer Resistance Protein Inhibitors [MoA]
NCIt Antineoplastic Agent Terminology
Organic Anion Transporter 1 Inhibitors [MoA]
dabrafenib 75 MG Oral Capsule [Tafinlar]
Narrower (3)
GSK 2118436
Tafinlar
dabrafenib mesylate
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma
G. Long
,
A. Hauschild
,
+20 authors
J. Kirkwood
2018
Corpus ID: 57720806
Abstract not available. Disclosures: Study sponsored by Novartis. Copyright 2018 SKIN
2017
2017
Dabrafenib Effective in Pediatric Glioma.
Cancer Discovery
2017
Corpus ID: 27376769
A phase I/II clinical trial suggests that dabrafenib shrinks or stabilizes low-grade gliomas in children with the BRAF V600E…
Expand
2016
2016
Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022).
G. Long
,
O. Hamid
,
+16 authors
A. Ribas
2016
Corpus ID: 56780039
TPS9596Background: The interaction between programmed death 1 (PD-1) and its ligands PD-L1 and PD-L2 represents a major pathway…
Expand
Review
2015
Review
2015
Evolution of melanocytic nevi under vemurafenib, followed by combination therapy with dabrafenib and trametinib for metastatic melanoma.
C. Giurcăneanu
,
C. Nitipir
,
L. Popa
,
A. Forsea
,
I. Popescu
,
Roxana Silvia Bumbăcea
Acta dermatovenerologica Croatica : ADC
2015
Corpus ID: 6600707
Treatment of advanced melanoma with selective BRAF and MEK inhibitors is associated with a series of mucocutaneous side effects…
Expand
2015
2015
Scientific Spring Meeting Friday March 20 , 2015 Dutch Society for Clinical Pharmacology and Biopharmacy Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie
W. Jacobs
,
N. Snoeren
,
+7 authors
R. van Hillegersberg
2015
Corpus ID: 34325487
Introduction: Low sensitivity of the standard methods of MRI and cerebrospinal fluid (CSF) cytology results in at least 25 % of…
Expand
2015
2015
Melanoma: Therapy combinations: celebrating more milestones
L. Hutchinson
Nature Reviews Clinical Oncology
2015
Corpus ID: 1961932
Review
2014
Review
2014
Trametinib plus dabrafenib for unresectable or metastatic melanoma with BRAF V600E or V600K mutations
J. Abraham
2014
Corpus ID: 74858407
O n January 9, 2014, the combination of trametinib and dabrafenib was granted accelerated approval by the US Food and Drug…
Expand
2014
2014
Melanoma: Blocking BRAF to the BRIM
M. Villanueva
Nature Reviews Clinical Oncology
2014
Corpus ID: 27219534
In the past few years, the treatment of melanoma has been revolutionised by the approval of the CTLA-4 antibody, ipilimumab, and…
Expand
2012
2012
Hauschild A, Grob JJ, Demidov LV et al.Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365
A. Hauschild
,
J. Grob
,
+18 authors
P. Chapman
2012
Corpus ID: 87827551
2012
2012
New class of kinase inhibitors poised to join the anticancer arsenal
Alisa Opar
Nature reviews. Drug discovery
2012
Corpus ID: 5632297
Long-standing efforts to develop drugs that target MEKs could soon come to fruition, moving the frontier to how best to combine…
Expand